ICMJE DISCLOSURE FORM

	2/47/2025	
Date:	3/17/2025	
Your Name:	Hjalmar Bouma	
Manuscript Title:	Acetylcysteïne-therapie voor de behandeling van paracetamolintoxicatie kan korter	
Manuscript Number (if known):	D8624	
content of your manuscript. "Rela affected by the content of the maindicate a bias. If you are in doubt." The author's relationships/activitic epidemiology of hypertension, you that medication is not mentioned. In item #1 below, report all supports.	e interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the ent of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be sted by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily state a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so. author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the emiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if medication is not mentioned in the manuscript. em #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time is for disclosure is the past 36 months.	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
		Time frame: Since the initial planning of the work		
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None None	Click the tab key to add additional rows.	
		Time frame: past 36 months		
2	Grants or contracts from	□ None		
	any entity (if not indicated in item #1 above).	Research grants to institute	Health Holland Public-Private Partnership (PPP) with Inflammatix (unrestricted research grant to UMCG); Health Holland Public-Private Partnership (PPP) with Octapharma (unrestricted research grant to UMCG); Health Holland Public-Private Partnership (PPP) with OSAsense (unrestricted research grant to UMCG); Dutch Kidney Foundation (unrestricted research grant to UMCG); Dutch Research Council (NWO) (unrestricted research grant to UMCG)	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
3	Royalties or licenses	None None	
4	Consulting fees	None Non	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	Non-profit travel support for meetings	All non-profit (EuroAnesthesia Munich, SLAS Barcelona) travel fee and waiver for congress registration costs.
8	Patents planned, issued or pending	Patent issued Patent pending	Patent (WO2021246868_A1) describing the use of chromanol, quinone, or hydroquinone compounds for the treatment of sepsis that is jointly owned by the University of Groningen and Sulfateq B.V. Recently filed a patent describing the measurement of 4-HNE in peripheral blood mononuclear cells to diagnose sepsis that is owned by the University of Groningen.
9	Participation on a Data Safety	[⊠] None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)		
	Monitoring Board or Advisory Board				
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	Unpaid memberships Paid memberships	Board member SepsisNet society (non-profit, unpaid), International Hibernation Society (non-profit, unpaid); member Institutional Review Board Bebo (financial compensation for time paid to UMCG), member scientific board Farmacotherapeutisch Kompas (financial compensation for time paid to UMCG)		
11	Stock or stock options	None None			
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None			
13	Other financial or non-financial interests	None None			
Plea [⊠]	Please place an "X" next to the following statement to indicate your agreement: I certify that I have answered every question and have not altered the wording of any of the questions on this form.				

3 12/13/2021 ICMJE Disclosure Form